Eli Lilly and Co. entered a definitive agreement to acquire Sigilon Therapeutics, Inc., a biopharmaceutical company looking to develop functional cures for a broad range of acute and chronic diseases, for approximately $34.6 million, plus a potential consideration of up to approximately $309.6 million. Since 2018, the companies have partnered to develop encapsulated cell therapies, including SIG-002, for the treatment of type 1 diabetes. The goal of these therapies is to free patients from co...